Lynparza™ (olaparib)

LYNPARZA® est indiqué dans 4 indications thérapeutiques. 

Lynpara (olaparib) est le premier inhibiteur de PARP (Poly-ADP-Ribose-Polymérase), qui permet aux femmes atteintes d'un cancer de l’ovaire récidivant sensible au platine avec une mutation BRCA (BReast CAncer) de prolonger la survie sans progression1-3 

Cancer du sein

Études cliniques

OlympiA

Videos

Prof. Evandro de Azambuja on genetic testing for early breast cancer patients

Dr. Kevin Punie on genetic testing for early breast cancer patients

Interview with Prof. de Azambuja on tailoring treatment options in early breast cancer

Interview with Dr. Punie on tailoring treatment options in early breast cancer

Podcast

Dr. Kevin Punie and Prof. Evandro de Azambuja discuss the key results of the phase III OlympiA study, evaluating adjuvant olaparib in patients with BRCA-mutated early breast cancer. Écoute maintenant.

Publications

Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer
Tutt ANJ et al. 2021 ( initial publication )

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Geyer CE et al. 2022 (Publication overall survival in OlympiA)

OlympiAD

Videos

Le professeur Duhoux présente les résultats de l’essai OlympiAD

Le professeur Duhoux répond aux quelques questions sur le testing gBRCA et le traitements des patients TNBC métastatiques

Publications

Olaparib for metastatic breast cancer in patients with a germline BRCA mutation
Robson M et al. 2017 (initial publication)

Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD.
Senkus-Konefka E et al. 2018 (Publication OlympiAD subgroup analysis)

OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer.
Robson M et al. 2019 (Publication overall survival in OlympiAD)

Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis.
Gelmon KA et al. 2021. (Lucy RWE publication)

MoA et recherche de mutations génétiques

Mécanisme d’action

Recherche de mutations génétiques

Website: https://www.idbrca.com/breast-home.html/

Pour vos patients

Journal pour les patients traités par Lynparza

Références

  1. LYNPARZA® 100 mg and 150 mg tabletten, samenvatting van de productkenmerken, meest recente versie
  2. www.riziv.fgov.be
  3. Weston VJ et al. The PARP inhibitor olaparib induces signicant killing of ATM-decient lymphoid tumour cells in vitro and in vivo. Blood. 2010;116(22):4578–4587.
  4. Weil MK and Chen AP. PARP inhibitor treatment in ovarian and breast cancer. Curr Probl Cancer. 2011;35(1):7–50.
  5. Aly A and Ganesan S. BRCA1, PARP, and 53BP1: Conditional synthetic lethality and synthetic viability. J Mol Cell Biol. 2011;3(1):66–74.
  6. Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405.
  7. Geyer CE et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022 Dec;33(12):1250-1268.
  8. Robson M et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6):523–533.
  9. Senkus-Konefka E, et al. 101 (PB-002) - Subgroup analysis of olaparib monotherapy versus chemotherapy by hormone receptor and BRCA mutation status in patients with HER2-negative metastatic breast cancer and a germline BRCA mutation: OlympiAD. Eur J Cancer. 2018;92(3):S19-S20.
  10. Robson M et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol. 2019;30(4):558–566.
  11. 11. Robson M et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377(6) Supplementary appendix.
  12. Tutt ANJ et al. Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med. 2021;384(25):2394–2405. Supplementary appendix.
  13. Kurian AW et al. Genetic testing and results in a population-based cohort of breast cancer patients and ovarian cancer patients. J Clin Oncol. 2019;37(15):1305–1315: Supplementary material.
  14. Baretta Z et al. Effect of BRCA germline mutations on breast cancer prognosis. A systematic review and meta-analysis. Medicine. 2016;95(40):e4975.
  15. Krammer J et al. Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res Treat. 2017;163(3):565–571.
  16. BRCA Gene Mutations: Cancer Risk and Genetic Testing. National Cancer Institute. Available at: https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet. Accessed April 2022.
  17. Song Y et al. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers. Cancer. 2020;126(2):271–280.
  18. Green L and Meric-Bernstam F. Risk of ipsilateral and contralateral cancer in BRCA mutation carriers with breast cancer. Curr Breast Cancer Rep. 2011;3(3):151–155.
  19. Valachis A et al. Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(3):443–455.
  20. Waks AG and Winer EP. Breast cancer treatment: a review. JAMA. 2019;321(3):288–300.
  21. Chalasani P and Livingston R. Differential chemotherapeutic sensitivity for breast tumors with “BRCAness”: a review. Oncologist. 2013;18(8):909–916. /span>
  22. Kennedy RD et al. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96(22):1659–1668.
  23. Sæther NH et al. Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review. Hered Cancer Clin Pract. 2018;16:9.
  24. Caramelo O et al. The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers–systematic review and meta-analysis. Hered Cancer Clin Pract. 2019;17:11.
  25. Consensus Guideline on Genetic Testing for Hereditary Breast Cancer. The American Society of Breast Surgeons. Available at: https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Genetic-Testing-for-Hereditary-Breast-Cancer.pdf. Accessed April 2022.
  26. Balmaña J et al. BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2011;22(suppl 6):vi31–vi34.

NS ID BE-3187-Revision date 06/2023-WEB Local code 1019

Ressources et supports

Retour au sommet